# Livongo Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/livongo-health

- Industry: Medical Devices & Equipment
- Headquarters: Mountain View, US
- Website: www.livongo.com/
- Total disclosed funding: $235M
- Latest round: Series E (Apr 11, 2018)
- Investors on record: 16

## About

Based in the US, Livongo Health, Inc. specializes in digital health solutions that empower individuals to manage chronic conditions effectively through connected devices and personalized coaching.Livongo Health, Inc. offers a digital platform for chronic care management, founded in 2014 in Mountain View, US. The company raised USD 18.5 bn in a merger with Teladoc Health Inc. in December 2020, following an IPO in July 2019, where it raised USD 355 mn. The CEO, Jason Gorevic, has a background in leading healthcare innovation.Livongo by Teladoc Health specializes in chronic care management through a digital health platform that provides patients with connected devices, expert coaching, and personalized health plans tailored to manage chronic conditions such as diabetes, hypertension, and weight challenges. The core offerings include connected health-monitoring devices, such as blood glucose meters and blood pressure monitors, which automatically upload health data to a mobile app for tracking and analysis. Users benefit from access to certified health coaches who provide ongoing support and personalized tips based on individual health data, enhancing their ability to make informed lifestyle changes. Livongo specifically targets U.S. markets, providing services to patients eligible through their employers or health plans, ensuring a wide client base that includes both individuals managing chronic conditions and the organizations that support their health management journeys.For the year 2019, Livongo reported revenue of USD 170.198 mn and an EBITDA of USD -54.47 mn. The company operates on a subscription-based model, where employers or health plans cover the costs of its services on behalf of their employees or members. Revenue is generated through partnerships with employers and health plans that integrate Livongo's services into their healthcare offerings. Transactions typically involve the deployment of health management programs that may include flagship services like Diabetes Management or Hypertension Management, which provide users with connected devices and access to expert coaching at no additional cost. The pricing structure is often bundled into the employer's health benefits, ensuring that users can seamlessly engage with the platform without direct costs for individual services. This model fosters long-term relationships with clients while enhancing user engagement and health outcomes through consistent monitoring and support.Livongo plans to leverage its merger with Teladoc Health to expand its product offerings and market reach. The company is focused on introducing new digital health solutions aimed at further integrating chronic care management into broader healthcare systems. Future developments are expected to be rolled out in the U.S. as the company seeks to enhance its services to existing clients while targeting new partnerships. The recent merger funding will be utilized to accelerate these initiatives and strengthen the technological infrastructure to support new product launches and market expansion.

## Funding rounds

- Series E, Apr 11, 2018, $105M — Draper Fisher Jurvetson, Kleiner Perkins, General Catalyst Partners, Sapphire Ventures, Merck Global Health Innovation Fund, Kinnevik, 7wireVentures, M12, Zaffre Investments, Echo Health Ventures
- Series D, Mar 14, 2017, $53M — Draper Fisher Jurvetson, Kleiner Perkins, General Catalyst Partners, Sapphire Ventures, SG Growth Capital, Merck Global Health Innovation Fund, Kinnevik, Wanxiang America Corporation, 7wireVentures, M12, Cowen Investment Management, Zaffre Investments, American Investment Holdings
- Series C, Apr 7, 2016, $50M — Draper Fisher Jurvetson, Kleiner Perkins, General Catalyst Partners, Sapphire Ventures, Merck Global Health Innovation Fund, Wanxiang America Corporation, BlueCross BlueShield Venture Partners, 7wireVentures, Cowen Investment Management, Zaffre Investments
- Series B, Mar 25, 2015, $20M — Draper Fisher Jurvetson, Kleiner Perkins, General Catalyst Partners
- Series A, Apr 22, 2014, $8.2M — General Catalyst Partners, Thoma Bravo, 7wireVentures

## Investors

- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series A, Series B, Series C, Series D, Series E
- Thoma Bravo (https://capitalatlas.ai/funds/thoma-bravo) — Series A
- 7wireVentures (https://capitalatlas.ai/funds/7wireventures) — Series A, Series C, Series D, Series E
- Draper Fisher Jurvetson (https://capitalatlas.ai/funds/draper-fisher-jurvetson) — Series B, Series C, Series D, Series E
- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series B, Series C, Series D, Series E
- Sapphire Ventures (https://capitalatlas.ai/funds/sapphire-ventures) — Series C, Series D, Series E
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series C, Series D, Series E
- Wanxiang America Corporation — Series C, Series D
- BlueCross BlueShield Venture Partners (https://capitalatlas.ai/funds/bluecross-blueshield-venture-partners) — Series C
- Cowen Investment Management — Series C, Series D
- Zaffre Investments (https://capitalatlas.ai/funds/zaffre-investments) — Series C, Series D, Series E
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series D
- Kinnevik (https://capitalatlas.ai/funds/kinnevik) — Series D, Series E
- M12 (https://capitalatlas.ai/funds/m12) — Series D, Series E
- American Investment Holdings (https://capitalatlas.ai/funds/american-investment-holdings) — Series D
- Echo Health Ventures (https://capitalatlas.ai/funds/echo-health-ventures) — Series E